1
Introduction 20
Over 30 million Americans suffer from diabetes. Evaluation of this patient 21 population suggests that tendon abnormalities (i.e., tendinopathies) such as collagen fibril 22 disorganization, increased tissue stiffness, and tissue degeneration are present in the 23 majority of diabetic individuals 1-3 . Notably, the high rate of tendinopathies in diabetic 24 individuals persists even when glucose levels are well controlled (hemoglobin 25 A1c<7) 2,4,5 . Given the high prevalence of diabetic tendinopathy, there is a critical need to 26 define the molecular process underlying the diabetic tendon phenotype. 27
Advanced glycation end-product (AGE) formation is a non-enzymatic process in 28 which free amine terminals are subjected to covalent modification by reactive glucose or 29 other carbonyl containing molecules. AGEs form at an accelerated rate in diabetes and 30 these modifications can result in non-enzymatic cross-links in long-lived extracellular 31 proteins such as tendon collagen, which increase tissue stiffness and alter tissue 32 mechanical properties 6-10 . Furthermore, circulating AGE adducts are able to interact with 33 the receptor for advanced glycation end-products (RAGE) to initiate a noxious feed 34 forward cycle of sustained inflammation and tissue damage 11 . In other tissues, 35 endogenous AGE formation as result of chronic hyperglycemia and spontaneous 36 oxidation of glycolytic intermediates contribute significantly to elevated levels of bound 37 and circulating AGE adducts in diabetic patients 12, 13 . Additionally, AGE-rich diets can 38 increase serum AGE levels and result in accumulation of AGEs in tendon of mice 14 . It is 39 not known, however, what role circulating AGEs play in the development and 40 progression of diabetic tendinopathy. organization in the ECM may be driven, in part, by the imbalance of energy (ATP) 48 demand and supply. We propose that AGEs contribute to the diabetic tendon phenotype 49 by activating cellular pathways that limit mitochondrial function, thereby interfering with 50 the capacity of tendon fibroblasts to maintain biosynthesis of tendon ECM. 51
In effort to better understand diabetes associated tendon pathology, we sought to 52 characterize impairments to energy producing systems and proliferative capacity of 53 tendon-derived fibroblasts in response to AGE treatment and high glucose containing 54 medium. We hypothesized that AGEs, in-vitro, would impair mitochondrial function and 55 proliferative capacity, independent of glucose concentrations. Further, we hypothesized 56 that AGEs and high glucose medium would reduce mitochondrial DNA (mtDNA) 57 content and further contribute to limitations imposed to energy producing pathways in 58 tendon fibroblasts. To advance our understanding of mitochondrial biogenesis and energy 59 production during AGE exposure, analysis of mitochondrial apoptotic regulators, as well 60 as regulators of mitochondrial energy metabolism was completed. This study provides 61 new functional and descriptive perspective of the AGE insult on tendon fibroblast 62 homeostasis. Figure 2a ). ATP production-coupled respiration was also significantly reduced in the HG 74 condition (p<0.0125, Figure 2a ). Basal respiration was significantly reduced at AGE-75 100μg/ml and AGE-200μg/ml compared to AGE-0μg/ml (p<0.0125, Figure 2b ), but no 76 glucose effect was observed (p>0.0125, Figure 2b ). Neither AGE treatment nor glucose 77 condition had a significant effect on maximal respiration (p>0.0125, Figure 2c ). AGE 78 treatment had no effect on proton leak (p>0.0125, Figure 2d ), but the HG condition 79 increased proton leak across the inner mitochondrial membrane (p<0.0125, Figure 2d ). 80
Coupling efficiency was significantly reduced at AGE-200μg/ml compared to AGE-81 0μg/ml (p<0.0125, Figure 2e ). Coupling efficiency was also significantly reduced in the 82 HG condition (p<0.0125, Figure 2e ). Spare respiratory capacity was significantly 83 increased at AGE-200μg/ml compared to AGE-0μg/ml (p<0.0125, Figure 2f ), but no 84 glucose effect was observed (p>0.0125, Figure 2f ). 85
Transcriptional Analysis of Extracellular Matrix Remodeling: Col1a1 and MMP9 86 mRNA transcript counts were significantly reduced in the AGE-200μg/ml compared to 87 AGE-0μg/ml (p<0.0125, Figure 3a&d ). Col3a1 mRNA transcript counts were 88 significantly increased in the AGE-50μg/ml and AGE-100μg/ml groups compared to 89 AGE-0μg/ml (p<0.0125, Figure 3b ). MMP2 mRNA transcript counts were significantly 90 increased in the AGE-100μg/ml compared to AGE-0μg/ml (p<0.0125, Figure 3c ). AGEs 91 had no effect on TIMP1 mRNA transcript counts (p<0.0125, Figure 3e ). No glucose 92 effect was observed for Col1a1, Col3a1, MMP2, MMP9, or TIMP1 (0<0.0125, Figure  93 3a-e). 94
Mitochondrial DNA Content: mtDNA content was significantly increased at 95 AGE-50μg/ml, AGE-100μg/ml, and AGE-200μg/ml compared to AGE-0μg/ml 96 (p<0.0125, Figure 4a ), but no effect of glucose condition was observed (p>0.0125, Figure  97 4a). Neither AGE treatment nor glucose condition had a significant effect on DNA 98 content when normalized to cell counts (p>0.0125, Figure 4b ). 99
Transcriptional Analysis of Mitochondrial Complexes: Ndufa1 mRNA transcript 100 counts were significantly increased at AGE-50μg/ml, AGE-100μg/ml, and AGE-101 200μg/ml compared to AGE-0μg/ml (p<0.0125, Figure 5a ), but no effect of glucose 102 condition was observed (p>0.0125, Figure 5a ). Sdha mRNA transcript counts were 103 significantly reduced at AGE-200μg/ml compared to AGE-0μg/ml (p<0.0125, Figure 5b) , 104 but no effect of glucose was observed (p>0.0125, Figure 5b ). A secondary direct 105 comparison to test the conditional main effect revealed that Sdha transcript counts were 106 significantly reduced at HG AGE-200μg/ml compared to HG AGE-0μg/ml (p<0.05, 107 Figure 5b ). Bcs1l mRNA was significantly reduced at AGE-50μg/ml, AGE-100μg/ml, 108 and AGE-200μg/ml compared to AGE-0μg/ml (p<0.0125, Figure 5c ). Bcs1l mRNA was 109 also significantly reduced in the HG condition (p<0.0125, Figure 5c ). Neither AGE 110 treatment nor glucose condition altered Cox4i1 mRNA transcript counts (p>0.0125, 111 Figure 5d ). MT-ATP6 mRNA transcript counts were significantly reduced at HG AGE-112 200μg/ml compared to HG AGE-0μg/ml (p<0.05, Figure 5e ), but no effect of glucose 113 was observed (p>0.0125, Figure 5e ). 114
Protein Analysis of Mitochondrial Complexes: Expression of complex III 115 (UQCRC2) was significantly increased at AGE-200μg/ml compared to AGE-0μg/ml 116 (p<0.017, Figure 6c ), but no glucose effect was observed (p>0.017, Figure 6c ). 117
Expression of complex I (NDUFB8), II (SDHB), IV (MTCO1), or V (ATP5A) were not 118 altered by either AGE treatment or glucose condition (p>0.017, Figure 6a , b, d, & e, 119 respectively). However, a significant interaction between AGE treatment and glucose 120 condition was observed for complex I (NDUFB8) and complex IV (MTCO1) (p<0.017, 121
Figure 6a&d). 122
Transcriptional Analysis of Mitochondrial Apoptosis: Bak1 mRNA transcript 123 counts were significantly reduced at AGE-100μg/ml and AGE-200μg/ml compared to 124 AGE-0μg/ml (p<0.0125, Figure 7a ), but no effect of glucose condition was observed 125 (p>0.0125, Figure 7a ). Bax and Casp8 mRNA transcript counts were significantly 126 reduced at HG AGE-200μg/ml compared to HG AGE-0μg/ml (p<0.05, Figure 7b&e , 127 respectively), but no effect of glucose was observed (p>0.0125, Figure 7b&e , 128 respectively). Bcl2 and Tgfbr3 mRNA transcript counts were significantly reduced at 129 AGE-200μg/ml compared to AGE-0μg/ml (p<0.0125, Figure 7c&f , respectively), but no 130 Discussion 137
AGE-induced non-enzymatic collagen cross-link formation in the ECM has been 138
proposed to increase tendon stiffness in diabetic individuals 6,7,10 . However, factors 139 contributing to tendon degeneration and collagen fibril disorganization in diabetic tendon 140 have not been extensively characterized. The detrimental effects of AGE associated 141 pathology are well described in non-tendon tissues and have been linked to several 142 diabetic complications such as cardiomyopathy, retinopathy, nephropathy, and 143 endothelial dysfunction 10,20 . In this study, we sought to address the effect of AGEs at the 144 cellular level to better understand factors that may contribute to the disorganization and 145 degeneration of tendon ECM noted in diabetic individuals. Using an in-vitro primary cell 146 culture system, we demonstrate dose-dependent AGE-induced reductions in proliferative 147 capacity and mitochondrial ATP production of tendon-derived fibroblasts. Additionally, 148
we demonstrate increased mtDNA content and modifications to mitochondrial complexes 149 and markers of apoptosis after AGE treatment. While previous research has established 150 AGE dependent mitochondrial and proliferative limitations 17,18,21 , these data, to the best 151 of our knowledge, are the first to show these impairments in tendon-derived fibroblasts. In-vitro and in-vivo data has indicated that elevated glucose availability can alter cell signaling dynamics and structural properties in tendon [28] [29] [30] . These data suggest that 160 glucose may contribute to tendon pathology, however conflicting reports exist and more 161 conclusive human data is needed to confirm hyperglycemia-associated tendon 162 degeneration in diabetes. 163
As evidenced, glucose does seem to be implicated in modulation of some tendon 164 cellular and structural properties 28-30 , however, the underlying mechanisms influencing 165 tendon degeneration in diabetic patients remain inconclusive. Couppé et al. 4 have 166 demonstrated that Achilles tendon Young's modulus (stiffness) is greater in diabetic 167 subjects compared to control subjects, but no difference exists between subjects with 168 well-controlled and poorly controlled diabetes. These data highlight that hyperglycemia 169 is unlikely to be the sole contributor of diabetic tendon pathology. In support of this 170 notion, we explored the role of AGEs on modulation of tendon cellular properties that 171 may consequently interfere with regulation and maintenance of the ECM. 172
Tendon fibroblast proliferation is a vital component to tendon development, 173 adaptation, and healing 31, 32 . An inability of tenocytes to proliferate in the presence of 174
AGEs would significantly precipitate the development of tendinopathy 38 . Tendinopathy is 175 thought to develop, in part, from a failed healing response to minor tendon damage 176 during loading. Specifically, delayed and abnormal healing is a common complication of 177 both type I and type II diabetes 33,34 . As evidence, tendinopathies in diabetic patients are 178 generally more pervasive and can present with more severe degeneration, which may, in 179 part, be driven by prolonged injury status 2,35,36 . We note dramatic impairments to tendon impairments to mitochondrial function and dynamics [15] [16] [17] [18] . Similarly, we report impaired 197 mitochondrial parameters and reduced ATP production-coupled respiration in tendon 198 fibroblasts treated with AGEs ( Figure 2a ). The role of ATP is diverse and essential for a 199 multitude of cellular processes including cell proliferation, contraction, and wound 200 healing. Specifically, ATP has been shown to promote biosynthesis of the ECM in 201 intervertebral disk cells 19 . In tendon, the resident fibroblast population maintains the 202 ECM, which is primarily composed of collagen. Due to the energy demanding nature of 203 ECM maintenance, it is possible, that in the presence of AGEs, limited ATP production 204 contributes to loss of organization in the ECM, which is commonly noted in diabetic 205 tendon 1-3 . While maximal respiration of tendon fibroblasts was unchanged due to 206 identical XFp seeding density, basal respiration was reduced after AGE treatment ( Figure  207 2b&c, respectively). In addition to loss of ATP production and reduced basal respiration, 208
we demonstrate that AGEs also impair electron transport coupling efficiency; thereby 209 increasing spare respiratory capacity of AGE treated tendon fibroblasts and indicating 210 overall reduction to electron transport efficiency (Figure 2e&f , respectively). 211
Interestingly, the HG condition increased proton leak across the inner mitochondrial 212 membrane and reduced ATP production and coupling efficiency, suggesting that glucose 213 alone can also impact electron transport efficiency ( Figure 2d ). It is important to note that 214 AGE and/or glucose-mediated mitochondrial impairments are likely not the sole 215 contributor of tendon ECM disorganization. For example, AGEs increase matrix 216 metalloproteinases (MMP) expression and activity, which may contribute in an additive 217 manner to enhanced degeneration in tendon ECM 38 . 218
To address our hypothesis that the presence of AGEs and resulting limited ATP 219 production contribute to loss of organization in the ECM, we completed gene analysis of 220 targets associated with ECM maintenance and remodeling. We note that AGE treatment 221 We also noted increased content of mtDNA after 48 hours of AGE treatment, 240 despite striking reductions to ATP production. mtDNA content can be used as an estimate 241 of mitochondrial volume 44 , however, contrary to our hypothesis, 48 hours of AGE 242 treatment resulted in increased mtDNA content in a dose dependent manner independent 243 of glucose condition (Figure 4a ). Based on our findings, it is plausible that the increase in 244 mtDNA in AGE-treated tendon fibroblasts was indicative of a compensatory response to 245 overcome the AGE insult and meet energy demands 45, 46 . In support of this theory, cells 246 under oxidative stress have been shown to increase mitochondria and mtDNA 47 . 247
Additionally, Kim et al. 46 have demonstrated a relationship between mtDNA content and 248 severity of histopathology in cancerous lesions, suggesting that increased mtDNA content 249 may be used as a measure of DNA injury and pathology. Despite this compensatory 250 response, functional mitochondrial limitations were still evident after 48 hours of AGE 251 treatment. Alternatively, it is possible that AGE-induced limitations to mitochondrial 252 biogenesis may result in failure of tendon fibroblasts to meet energy demands. For 253 example, mtDNA is more susceptible to mutation than nuclear DNA and AGEs have 254 been shown to induce damage to mtDNA, which could ultimately impact mitochondrial 255 biogenesis 48,49 . However, further molecular work is needed to conclusively define the 256 pathway of AGE-mediated mitochondrial damage. To confirm that mtDNA content 257 measurements were not falsely elevated by an increase in total DNA, despite equal DNA 258 loading per PCR reaction, we normalized total DNA yield to cell counts and noted no 259 difference in DNA content with either glucose condition or AGE treatment ( Figure 4b ). and glucose condition was observed in complex I (NDUFB8, Figure 6a ) and complex IV 286 (MTCO1, Figure 6d ). These results merit further work to discover mechanistic pathways 287 by which AGEs limit mitochondrial function during long-term AGE exposure. 288
To assess the impact of AGEs on mitochondrial-related tendon fibroblast 289 apoptosis, we completed analysis of associated gene transcripts and measurement of 290 superoxide production. Transcript counts of pro-apoptotic gene Bak1 were reduced with 291 AGE treatment (Figure 7a ). Additionally, pro-apoptotic Bax mRNA expression was 292 reduced only in the HG AGE-200μg/ml group compared to HG AGE-0μg/ml (Figure 7b ). 293
Although these findings are contrary to previous work 21 , it is possible that these may be 294 compensatory responses to AGE-mediated apoptotic signals. In agreement with previous 295 work by Hu et al. 21 , expression of Bcl2 mRNA, an anti-apoptotic mediator, was reduced 296 with AGE treatment (Figure 7c ). Previous reports have indicated an inverse relationship 297 between Bcl2 and ROS, where ROS may act to reduce expression of Bcl2 and sensitize 298 cells to apoptosis 52 . In agreement, our data demonstrate increased production of 299 superoxide, a reactive anion species, after AGE treatment (Figure 8 ). Further, cytochrome 300 c release is suppressed by Bcl2, but is promoted by Bak1 and Bax. Cytochrome c release 301 will ultimately result in caspase activation 53 . Previous reports indicate AGE treatment 302 induces caspase activation 21,54 , however we did not note any AGE-induced changes to 303
Casp3 mRNA (Figure 7d ) but did note reduced Casp8 mRNA in the HG AGE-200μg/ml 304 group compared to HG AGE-0μg/ml (Figure 7e ). Finally, transcript counts of Tgfbr3 305
were reduced with AGE treatment (Figure 7f ). Tgfbr3 overexpression has been shown to 306 increase Bax and Bcl2 expression, as well as promote activation of caspase 3 55 . Casp3 307 mRNA expression was reduced in the HG condition and was the only target associated 308 with apoptosis to be affected by glucose (Figure 7d ). From these data, it is evident that 309
AGEs alter transcriptional regulation of gene transcripts associated with apoptosis, 310 however, we are limited in our interpretation and further post-translational and activity 311 assays are needed to define the precise mechanisms by which AGEs may induce 312 apoptosis in diabetic tendinopathy. 313
In summary (Figure 9 ), we demonstrate that AGEs, which are elevated in serum 314 of diabetic individuals, impair proliferative capacity, ATP production, and electron 315 transport chain efficiency. Additionally we demonstrate that AGEs alter regulation of 316 mitochondrial complex expression and gene transcripts associated with apoptosis. While 317 the HG condition did impact some mitochondrial parameters, AGEs appear to be the Protein Expression: Cultured cells were lysed in RIPA buffer containing 50mM 441
Tris-HCl, 150mM NaCl, 2mM EDTA, 2mM EGTA, 0.5% sodium deoxycholate, 1% 442 Triton X-100, 0.1% SDS, 50mM NaF, 0.2mM Na 3 VO 4, and 0.2% protease inhibitor 443 cocktail (Sigma). Samples were prepared as described previously 64 . Equal amounts of 444 protein (15μg) were separated in duplicate on an Any-kD TGX polyacrylamide gel 445 (BioRad). Protein was transferred to a PVDF membrane (TransBlot Turbo, BioRad) and 446 blocked for 24 hours at 4°C in 5% blotting-grade blocker (BioRad). Blots were incubated 447 in primary OXPHOS antibody (1:1000, 110413, Abcam, Cambridge, MA) and then 448 HRP-conjugated goat anti-mouse antibody (1:5000, 31430, Invitrogen), each for 2 hours 449 at room temperature. Bands of interest were compared against positive control (Rat Heart 450 Mitochondria, Abcam) and all targets were probed on the same membrane, but required 451 different exposure times using signal accumulation mode (ChemiDoc, BioRad). Volume 452 intensity analysis of matched exposure duration for each target was completed using 453 Image Lab Version 6.0.1 (BioRad). Total protein volume intensity obtained by UV 454 activated Stain-Free imaging was used for data normalization. 
